MX337650B - Metodos para predecir el desenlace clinico del cancer. - Google Patents

Metodos para predecir el desenlace clinico del cancer.

Info

Publication number
MX337650B
MX337650B MX2012005822A MX2012005822A MX337650B MX 337650 B MX337650 B MX 337650B MX 2012005822 A MX2012005822 A MX 2012005822A MX 2012005822 A MX2012005822 A MX 2012005822A MX 337650 B MX337650 B MX 337650B
Authority
MX
Mexico
Prior art keywords
cancer
methods
genes
clinical outcome
prognosis
Prior art date
Application number
MX2012005822A
Other languages
English (en)
Other versions
MX2012005822A (es
Inventor
Joffre B Baker
Maureen T Cronin
Francois Collin
mei-lan Liu
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2012005822A publication Critical patent/MX2012005822A/es
Publication of MX337650B publication Critical patent/MX337650B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a métodos para determinar el pronóstico y el tratamiento adecuado para pacientes con diagnóstico de cáncer, basándose en los niveles de expresión de uno más biomarcadores. De manera más particular, la invención se refiere a la identificación de genes, o de conjuntos de genes, capaces de distinguir a los pacientes de cáncer de mama con buen pronóstico clínico respecto de aquellos que tienen un mal pronóstico clínico. La invención también proporciona métodos para obtener un informe genómico personalizado para un paciente de cáncer. La invención también se refiera a sistemas de computadora y software para análisis de datos utilizando los métodos de pronóstico y estadística divulgados en la presente.
MX2012005822A 2009-11-23 2010-11-19 Metodos para predecir el desenlace clinico del cancer. MX337650B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26376309P 2009-11-23 2009-11-23
PCT/US2010/057490 WO2011063274A2 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer

Publications (2)

Publication Number Publication Date
MX2012005822A MX2012005822A (es) 2012-06-19
MX337650B true MX337650B (es) 2016-03-14

Family

ID=44060376

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016003089A MX363817B (es) 2009-11-23 2010-11-19 Métodos para predecir el desenlace clínico del cáncer.
MX2012005822A MX337650B (es) 2009-11-23 2010-11-19 Metodos para predecir el desenlace clinico del cancer.
MX2019003811A MX391499B (es) 2009-11-23 2010-11-19 Metodos para predecir el desenlace clinico del cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016003089A MX363817B (es) 2009-11-23 2010-11-19 Métodos para predecir el desenlace clínico del cáncer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019003811A MX391499B (es) 2009-11-23 2010-11-19 Metodos para predecir el desenlace clinico del cancer.

Country Status (13)

Country Link
US (4) US20110123990A1 (es)
EP (4) EP3556867A1 (es)
JP (7) JP5964752B2 (es)
AU (1) AU2010321829B2 (es)
CA (2) CA3043089A1 (es)
DK (1) DK2504451T3 (es)
ES (1) ES2735993T3 (es)
HU (1) HUE044374T2 (es)
IL (5) IL219051A (es)
MX (3) MX363817B (es)
NZ (1) NZ599194A (es)
PL (1) PL2504451T3 (es)
WO (1) WO2011063274A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
MX2010014280A (es) * 2008-06-26 2011-05-23 Dana Farber Cancer Inst Inc Distintivos y determinantes asociados con metástasis y método para utilizarlos.
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
JP5964752B2 (ja) * 2009-11-23 2016-08-03 ジェノミック ヘルス， インコーポレイテッド 癌の臨床転帰を予測する方法
MX375138B (es) 2010-01-11 2025-03-06 Genomic Health Inc Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal.
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
US20120053253A1 (en) 2010-07-07 2012-03-01 Myriad Genetics, Incorporated Gene signatures for cancer prognosis
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
CA2831074A1 (en) * 2011-03-26 2012-10-04 Oregon Health And Science University Gene expression predictors of cancer prognosis
CA2840472A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
WO2013006495A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
AU2012281152B2 (en) * 2011-07-13 2017-09-07 The Multiple Myeloma Research Foundation, Inc. Methods for data collection and distribution
EP2744917A4 (en) * 2011-08-16 2015-10-14 Oncocyte Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BREAST CANCER
WO2013070521A1 (en) * 2011-11-08 2013-05-16 Genomic Health, Inc. Method of predicting breast cancer prognosis
JP5805518B2 (ja) * 2011-12-21 2015-11-04 株式会社島津製作所 マルチプレックス大腸がんマーカーパネル
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
EP2839034A4 (en) * 2012-04-20 2016-01-06 Sloan Kettering Inst Cancer ASSOCIATED GENE EXPRESSION PROFILES ASSOCIATED WITH METASTASISING BREAST CANCER
WO2014055398A1 (en) 2012-10-05 2014-04-10 Siemens Healthcare Diagnostics Inc. Method for detecting an increased risk or incidence of colorectal cancer
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
US10181008B2 (en) * 2013-05-30 2019-01-15 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
WO2014195032A1 (en) * 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2015138769A1 (en) * 2014-03-12 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for assessing patients with non-small cell lung cancer
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
EP3274440B1 (en) 2015-03-27 2026-03-04 Exact Sciences Corporation Detecting esophageal disorders
KR102811214B1 (ko) 2015-10-30 2025-05-27 이그잭트 사이언시즈 코포레이션 복합 증폭 검출 분석 및 혈장으로부터 dna의 분리 및 검출 방법
EP3389481A4 (en) 2015-12-18 2019-05-22 Clear Gene, Inc. PROCESSES, COMPOSITIONS, KITS AND DEVICES FOR FAST LANALYSIS OF BIOLOGICAL MARKERS
SG11201901466PA (en) * 2016-09-07 2019-03-28 Agency Science Tech & Res A method of identifying risk of cancer and therapeutic options
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
JP7289264B2 (ja) 2017-01-27 2023-06-09 エグザクト サイエンシーズ コーポレーション メチル化ｄｎａの分析による結腸腫瘍の検出
WO2018212192A1 (ja) * 2017-05-18 2018-11-22 京都府公立大学法人 癌の予後及び／又は転移可能性を評価する方法及びマーカー
US12275994B2 (en) * 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
CA3036161C (en) 2017-11-13 2023-03-28 The Multiple Myeloma Research Foundation, Inc. Integrated, molecular, omics, immunotherapy, metabolic, epigenetic, and clinical database
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
US11549152B2 (en) * 2018-03-08 2023-01-10 University Of Notre Dame Du Lac Products for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
US20220120753A1 (en) * 2018-09-21 2022-04-21 The University Of Tokyo Method for determining prognosis of cancer
JP2019032334A (ja) * 2018-10-03 2019-02-28 イムノヴィア・アクチエボラーグ 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
MX2021006560A (es) * 2018-12-08 2021-11-17 Pfs Genomics Inc Perfilado transcriptómico para prognosis de cáncer de mama.
SG11202111940XA (en) * 2019-05-03 2021-12-30 Dcgen Co Ltd Method of predicting cancer prognosis and composition for same
CN111235270B (zh) * 2019-08-29 2022-04-29 北京臻知医学科技有限责任公司 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒
US12165747B2 (en) * 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
AU2022220330A1 (en) * 2021-02-12 2023-09-14 Mammogen, Inc. Biomarkers for the diagnosis of breast cancer
WO2022192128A2 (en) * 2021-03-08 2022-09-15 Castle Biosciences, Inc. Determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores
CN117116345B (zh) * 2023-07-24 2025-09-16 中国人民解放军军事科学院军事医学研究院 一种基于基因调控网络构建患者生存网络的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1410011T3 (da) 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DK3115470T3 (en) * 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2905579T3 (es) * 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
WO2005086891A2 (en) * 2004-03-05 2005-09-22 Rosetta Inpharmatics Llc Classification of breast cancer patients using a combination of clinical criteria and informative genesets
CA2582739A1 (en) * 2004-09-30 2006-04-13 Bayer Healthcare Ag Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
JP2008534002A (ja) 2005-04-01 2008-08-28 エヌシィーシィー テクノロジー ベンチャーズ ピィーティーイー．リミテッド 乳癌の分類に関する材料および方法
WO2006133460A2 (en) 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
US7888019B2 (en) * 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US20100234292A1 (en) * 2007-04-16 2010-09-16 Ipsogen Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
WO2009095319A1 (en) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
CA2723972A1 (en) * 2008-05-12 2009-11-19 Genomic Health Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
JP5964752B2 (ja) * 2009-11-23 2016-08-03 ジェノミック ヘルス， インコーポレイテッド 癌の臨床転帰を予測する方法

Also Published As

Publication number Publication date
JP2022169647A (ja) 2022-11-09
JP2021058207A (ja) 2021-04-15
PL2504451T3 (pl) 2019-09-30
CA3043089A1 (en) 2011-05-26
JP2022166064A (ja) 2022-11-01
JP7823012B2 (ja) 2026-03-03
IL219051A (en) 2016-12-29
JP2016214245A (ja) 2016-12-22
US20190241967A1 (en) 2019-08-08
EP2504451B1 (en) 2019-06-05
IL264072B (en) 2020-08-31
EP3556867A1 (en) 2019-10-23
EP3739060A1 (en) 2020-11-18
US20170211154A1 (en) 2017-07-27
IL276487A (en) 2020-09-30
EP2504451A2 (en) 2012-10-03
MX391499B (es) 2025-03-21
US20110123990A1 (en) 2011-05-26
WO2011063274A3 (en) 2014-03-27
CA2776751A1 (en) 2011-05-26
MX363817B (es) 2019-04-04
CA2776751C (en) 2019-07-02
DK2504451T3 (da) 2019-08-05
MX2019003811A (es) 2019-08-05
MX2012005822A (es) 2012-06-19
HUE044374T2 (hu) 2019-10-28
IL257063B (en) 2019-01-31
IL276487B (en) 2022-03-01
JP5964752B2 (ja) 2016-08-03
ES2735993T3 (es) 2019-12-23
JP2013514058A (ja) 2013-04-25
JP7042717B2 (ja) 2022-03-28
IL219051A0 (en) 2012-06-28
AU2010321829A1 (en) 2012-05-03
JP2018196385A (ja) 2018-12-13
EP4350001A3 (en) 2024-06-19
NZ599194A (en) 2014-07-25
US20210062275A1 (en) 2021-03-04
IL249159A0 (en) 2017-01-31
EP4350001A2 (en) 2024-04-10
JP2024037948A (ja) 2024-03-19
WO2011063274A2 (en) 2011-05-26
AU2010321829B2 (en) 2015-07-30
IL264072A (en) 2019-02-28
EP2504451A4 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
MX363817B (es) Métodos para predecir el desenlace clínico del cáncer.
Pallis et al. Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging?
Wang et al. Predictors of the survival of patients with chondrosarcoma of bone and metastatic disease at diagnosis
WO2005086891A3 (en) Classification of breast cancer patients using a combination of clinical criteria and informative genesets
MX338883B (es) Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata.
NZ593225A (en) Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis
ES2938766T3 (es) Firmas génicas para el pronóstico de cáncer
IN2012DN04944A (es)
MX337333B (es) Metodos y sistemas para evaluar resultados clinicos.
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
MX351626B (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2019000091A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
Deshpande et al. Development of a claims-based algorithm to identify colorectal cancer recurrence
Pavlík et al. Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000–2008
Lund et al. Development and validation of a 5‐year mortality prediction model using regularized regression and Medicare data
Alam et al. Prostate cancer genomics: Comparing results from three molecular assays
Ku et al. Risk prediction models of locoregional failure after radical cystectomy for urothelial carcinoma: external validation in a cohort of korean patients
Da et al. Upregulation of the long non-coding RNA FAM83H-AS1 in gastric cancer and its clinical significance
Mello et al. Machine learning supports long noncoding rnas as expression markers for endometrial carcinoma
Kim et al. Clinical implications and prognostic values of prostate cancer susceptibility candidate methylation in primary nonmuscle invasive bladder cancer
Jahreiβ et al. Long-term Overall Survival after External Beam Radiotherapy for Localised Prostate Cancer
WO2010091296A3 (en) Emx2 in cancer diagnosis and prognosis
WO2006065940A3 (en) Identification and use of prognostic and predictive markers in cancer treatment
Tang et al. Pan‐cancer analysis reveals molecular signatures for predicting matrix stiffness in solid tumors
Samuels et al. The cancer genome

Legal Events

Date Code Title Description
FG Grant or registration